Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®).
GLP-1 受體激動劑與自殺意念：使用世界衛生組織藥物監測數據庫 (VigiBase®) 的重複研究。
J Affect Disord 2024-10-21
The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS).
葡萄糖樣肽-1 受體激動劑（GLP-1 RAs）與自殺行為之關聯：對食品藥物管理局不良事件報告系統（FAERS）的報告。
Expert Opin Drug Saf 2024-02-14
Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.
與semaglutide、liraglutide和tirzepatide相關的精神科不良事件：提交至EudraVigilance數據庫的個別案例安全報告的藥物警戒分析。
Int J Clin Pharm 2024-03-26
Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.
GLP-1 受體激動劑與自殺或自我傷害行為之潛在關聯性探討：基於 FDA 不良事件報告系統資料庫的藥物監察研究。
BMC Med 2024-02-17
Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database.
GLP-1 受體激動劑與自殺意念：歐洲藥物監視數據分析。
Pharmaceuticals (Basel) 2024-02-27
Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes : A Target Trial Emulation Study.
糖尿病老年患者中胰高血糖素樣肽-1受體激動劑與自殺意念和行為風險：一項針對性試驗模擬研究。
Ann Intern Med 2024-07-15
Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study.
糖尿病和肥胖患者中，胰高血糖素樣肽-1受體激動劑與自殺意念和自我傷害的關聯：一項傾向加權的基於人群的隊列研究。
Diabetologia 2024-08-05
Association between glucagon-like peptide-1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database.
胰高血糖素樣肽-1 受體激動劑與自殺風險之間的關聯：全球藥物監測數據庫的綜合分析。
Diabetes Obes Metab 2024-08-20
Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality.
來自世界衛生組織數據的 Semaglutide、Liraglutide 與自殺傾向的不成比例分析。
JAMA Netw Open 2024-08-20
The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy.
使用胰高血糖素樣肽-1受體激動劑治療的肥胖患者中抑鬱、焦慮和自殺行為的風險。
Sci Rep 2024-10-18